What's coming at ECO 2026 the next three days

What's coming the next three days at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey:

Wednesday, May 13

REDEFINE 1 Analysis: Presentations on how CagriSema impacts BMI and waist-to-height ratio.

Body Composition: Data regarding the effect of CagriSema on muscle strength and physical function, which is a critical area of interest for "quality" of weight loss.

STEP UP Trial: A post hoc analysis of higher-dose semaglutide (7.2 mg) and how long it takes patients to reach specific weight reduction thresholds.

Thursday, May 14

OASIS 4 Results: Post hoc analysis of Oral Semaglutide (25 mg), specifically looking at gastrointestinal (GI) tolerability and its relationship to weight loss efficacy.

Quality of Life: Data from REDEFINE 1 regarding how CagriSema improves the quality of life for patients that began with poor physical function.

Drug Interactions: Findings on whether CagriSema affects the exposure of common medications like Warfarin or Atorvastatin.

Friday, May 15

Dose Optimization: Further characterization of dose reductions in the REDEFINE 1 trial and the relationship between the mean dose of CagriSema and total weight loss.

Elderly Population (STEP Trials): A pooled analysis of the safety and efficacy of semaglutide in individuals aged 65 and older.

Special Populations: Data on how renal or hepatic impairment affects the pharmacokinetics and safety of subcutaneous cagrilintide.